CT-95
IND- Indications
- Ovarian cancer, Lung cancer, Pancreatic cancer, Solid tumors
Company intelligence / Profile preview
Link Immunotherapeutics
Seattle, Washington, United Stateslinkedin.com ↗
- Ownership
- Private
- Employees
- ~12
- Development stage
- Other
01
Overview
Link Immunotherapeutics develops next-generation immunotherapies with enhanced tumor selectivity using bispecific antibodies and related modalities. Their lead program targets mesothelin-expressing solid tumors with a bispecific T-cell engager currently in preclinical development. The company’s approach aims to improve efficacy while reducing off-tumor toxicity by balancing affinity/avidity and leveraging both validated and novel target combinations. No clinical results have been published yet; the pipeline remains at the discovery/preclinical stage with one asset noted at Phase I status overall.
- Therapeutic areas
- Oncology
- Modalities
- Bispecific T-cell Engager (BiTE)Bispecific antibodyMonoclonal antibodies (mAbs)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Collaborations with industry-leading partners are mentioned but not named specifically.
Beyond the preview
Go deeper on Link Immunotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Link Immunotherapeutics.